BCRXHIGH SIGNALFINANCIAL10-K

BCRX achieved a dramatic turnaround from -$88.9M net loss to $263.9M net income, driven by massive operating improvements and the Astria merger integration.

This represents a fundamental transformation of the business model from a loss-making operation to profitability, with operating income swinging from -$2.5M to $341M. The merger with Astria appears to be the primary catalyst, though management acknowledges integration risks and warns that anticipated synergies may not materialize.

Comparing 2026-02-26 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

The financial statements reveal a company in dramatic transition, with operating cash flow surging from -$52M to $347M and the business achieving its first profitable year. However, this transformation came with significant leverage increases (total debt up 143% to $298M) and operational restructuring (inventory down 83%). The substantial improvement in stockholders' equity from -$476M to -$119M, while still negative, suggests the company is on a path toward financial stability, though the high debt load and integration costs present ongoing risks to sustain this performance.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+13508.9%
-$2.5M→$341.0M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Share Buybacks
Cash Flow
+1120%
$5K→$61K

Share repurchases increased 1120% — management returning capital, signals confidence in intrinsic value.

Operating Cash Flow
Cash Flow
+767.8%
-$52.0M→$347.4M

Operating cash flow surged 767.8% — exceptional cash generation, highest quality earnings signal.

Net Income
P&L
+396.9%
-$88.9M→$263.9M

Net income grew 396.9% — bottom-line growth signals improving overall business health.

Total Debt
Balance Sheet
+143.2%
$122.6M→$298.1M

Debt increased 143.2% — substantial leverage increase; assess whether deployed for growth or covering losses.

Inventory
Balance Sheet
-82.7%
$31.3M→$5.4M

Inventory drawn down 82.7% — strong sell-through or deliberate destocking; watch for supply constraints.

Stockholders Equity
Balance Sheet
+75%
-$475.9M→-$119.2M

Equity base grew 75% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Accounts Receivable
Balance Sheet
+35.1%
$79.1M→$106.8M

Receivables surged 35.1% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Total Liabilities
Balance Sheet
-34.5%
$966.4M→$633.3M

Liabilities reduced 34.5% — deleveraging improves balance sheet strength and financial flexibility.

SG&A Expense
P&L
+31%
$266.1M→$348.6M

SG&A up 31% — significant increase in sales or administrative costs, monitor impact on operating leverage.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-25
ADDED
We may not achieve sustained profitability, and we may need to raise additional capital in the future.
If we are unable to raise capital or obtain financing if and when needed, we may need to adjust our operations.
If the benefits of the Merger do not meet the expectations of investors or securities analysts, the market price of our common stock may decline.
In addition, combining Astria with our business may be more difficult, costly or time consuming than expected and the combined company may fail to realize the anticipated benefits, cost savings and synergies of the Merger.
The commercial viability of any approved product could be compromised if the product is less effective than expected, causes undesirable side effects that either were not previously identified or were worse than expected, or fails to achieve market acceptance by physicians, patients, third-party payors, health authorities, and others.
+7 more — sign up free →
REMOVED
Government exercising any options under our current procurement contract, and our ability to execute any such order; additional regulatory approvals, or milestones, royalties or profit from sales of our products by us or our partners; the implementation of our business model, strategic plans for our business, products, product candidates and technology; our ability to establish and maintain collaborations or out-license rights to our products and product candidates; plans, programs, progress and potential success of our collaborations, including with Torii Pharmaceutical Co., Ltd.
We have incurred losses since our inception and may never achieve sustained profitability.
If we are unable to raise capital if and when needed, we may need to adjust our operations.
If we fail to obtain additional financing or acceptable partnership arrangements if and when needed, we may be unable to complete the development and commercialization of our products and product candidates or continue operations.
There can be no assurance that our or our partners commercialization efforts, methods, and strategies for our products or technologies will succeed, and our future revenue generation is uncertain.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →